Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer

Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Kufe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The oncogenic MUC1-C protein and the TWIST1 epithelial–mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.

Original languageEnglish
Pages (from-to)1744-1754
Number of pages11
JournalMolecular cancer therapeutics
Volume18
Issue number10
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Paclitaxel
Twist-Related Protein 1
Protein C
Drug Resistance
Genes
Transcription Factors
Stem Cells
RNA
Phenotype
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hata, T., Rajabi, H., Yamamoto, M., Jin, C., Ahmad, R., Zhang, Y., ... Kufe, D. (2019). Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer. Molecular cancer therapeutics, 18(10), 1744-1754. https://doi.org/10.1158/1535-7163.MCT-19-0156

Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer. / Hata, Tsuyoshi; Rajabi, Hasan; Yamamoto, Masaaki; Jin, Caining; Ahmad, Rehan; Zhang, Yan; Kui, Ling; Li, Wei; Yasumizu, Yota; Hong, Deli; Miyo, Masaaki; Hiraki, Masayuki; Maeda, Takahiro; Suzuki, Yozo; Takahashi, Hidekazu; Samur, Mehmet; Kufe, Donald.

In: Molecular cancer therapeutics, Vol. 18, No. 10, 01.01.2019, p. 1744-1754.

Research output: Contribution to journalArticle

Hata, T, Rajabi, H, Yamamoto, M, Jin, C, Ahmad, R, Zhang, Y, Kui, L, Li, W, Yasumizu, Y, Hong, D, Miyo, M, Hiraki, M, Maeda, T, Suzuki, Y, Takahashi, H, Samur, M & Kufe, D 2019, 'Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer', Molecular cancer therapeutics, vol. 18, no. 10, pp. 1744-1754. https://doi.org/10.1158/1535-7163.MCT-19-0156
Hata, Tsuyoshi ; Rajabi, Hasan ; Yamamoto, Masaaki ; Jin, Caining ; Ahmad, Rehan ; Zhang, Yan ; Kui, Ling ; Li, Wei ; Yasumizu, Yota ; Hong, Deli ; Miyo, Masaaki ; Hiraki, Masayuki ; Maeda, Takahiro ; Suzuki, Yozo ; Takahashi, Hidekazu ; Samur, Mehmet ; Kufe, Donald. / Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 10. pp. 1744-1754.
@article{b77971c113634d93baf853082126546e,
title = "Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer",
abstract = "The oncogenic MUC1-C protein and the TWIST1 epithelial–mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.",
author = "Tsuyoshi Hata and Hasan Rajabi and Masaaki Yamamoto and Caining Jin and Rehan Ahmad and Yan Zhang and Ling Kui and Wei Li and Yota Yasumizu and Deli Hong and Masaaki Miyo and Masayuki Hiraki and Takahiro Maeda and Yozo Suzuki and Hidekazu Takahashi and Mehmet Samur and Donald Kufe",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-19-0156",
language = "English",
volume = "18",
pages = "1744--1754",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Targeting MUC1-C inhibits TWIst1 signaling in triple-negative breast cancer

AU - Hata, Tsuyoshi

AU - Rajabi, Hasan

AU - Yamamoto, Masaaki

AU - Jin, Caining

AU - Ahmad, Rehan

AU - Zhang, Yan

AU - Kui, Ling

AU - Li, Wei

AU - Yasumizu, Yota

AU - Hong, Deli

AU - Miyo, Masaaki

AU - Hiraki, Masayuki

AU - Maeda, Takahiro

AU - Suzuki, Yozo

AU - Takahashi, Hidekazu

AU - Samur, Mehmet

AU - Kufe, Donald

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The oncogenic MUC1-C protein and the TWIST1 epithelial–mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.

AB - The oncogenic MUC1-C protein and the TWIST1 epithelial–mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.

UR - http://www.scopus.com/inward/record.url?scp=85072849098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072849098&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-19-0156

DO - 10.1158/1535-7163.MCT-19-0156

M3 - Article

C2 - 31308076

AN - SCOPUS:85072849098

VL - 18

SP - 1744

EP - 1754

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -